Bayer joins $25M investment in data-driven digital health startup

Medopad, an artificial intelligence startup using data from provider databases and patient devices for remote disease monitoring, raised $25 million in a Series B funding round led by Bayer's life sciences innovation arm.

Along with the investment, Bayer will also work with Medopad to build AI-driven digital therapies specifically to track heart health. The startup has ongoing projects with Johnson & Johnson's Janssen Pharmaceuticals to develop a digital biomarker for Alzheimer's disease; it previously partnered with Apple to develop a medication management and adherence Apple Watch app for chemotherapy patients.

Medopad is also a member of the Discover-NOW initiative, alongside Google Health, AstraZeneca and IBM, to create the Health Data Research Hub for Real-World Evidence.

More articles on health IT:
Malcolm Gladwell: 3 reasons for the 'lag' between innovation and adoption
Lasers can hack Amazon Alexa, other smart speakers from afar, study finds
DNA-testing company informs consumers of data breach

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers